Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Jacobs

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Neurology|March 1, 2006
Isolated global amnesia associated with autoimmune thyroid diseaseAlan Jacobs, James Root, Wilfred Van Gorp
Journal of Gerontological Nursing|March 28, 2022
Medication Identification Device to Reduce Medication Errors in Nursing Homes: A Controlled Pilot StudyAmy Vogelsmeier, Alan Jacobs, Carly Owen, et al.
International Journal of MS Care|May 16, 2020
Effect of Alemtuzumab Infusions on Vital Signs: A Prospective Observational Study in Patients with Relapsing-Remitting Multiple SclerosisAngel Chinea, William David Honeycutt, Tamara Miller, et al.
The American Journal of Pathology|April 12, 2002
Clonal human (hNT) neuron grafts for stroke therapy: neuropathology in a patient 27 months after implantationPeter T Nelson, Douglas Kondziolka, Lawrence Wechsler, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 11, 2021
Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MSJens Kuhle, Nadia Daizadeh, Pascal Benkert, et al.
Critical Care Medicine|May 25, 2012
Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trialBruno François, Charles-Edouard Luyt, Anthony Dugard, et al.
Therapeutic Advances in Neurological Disorders|May 26, 2021
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trialAlasdair J Coles, Douglas L Arnold, Ann D Bass, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2019
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studiesGiancarlo Comi, Raed Alroughani, Aaron L Boster, et al.
Science Translational Medicine|December 21, 2022
Mitochondrial augmentation of hematopoietic stem cells in children with single large-scale mitochondrial DNA deletion syndromesElad Jacoby, Omer Bar-Yosef, Noah Gruber, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Neurology|March 1, 2006
Isolated global amnesia associated with autoimmune thyroid diseaseAlan Jacobs, James Root, Wilfred Van Gorp
Journal of Gerontological Nursing|March 28, 2022
Medication Identification Device to Reduce Medication Errors in Nursing Homes: A Controlled Pilot StudyAmy Vogelsmeier, Alan Jacobs, Carly Owen, et al.
International Journal of MS Care|May 16, 2020
Effect of Alemtuzumab Infusions on Vital Signs: A Prospective Observational Study in Patients with Relapsing-Remitting Multiple SclerosisAngel Chinea, William David Honeycutt, Tamara Miller, et al.
The American Journal of Pathology|April 12, 2002
Clonal human (hNT) neuron grafts for stroke therapy: neuropathology in a patient 27 months after implantationPeter T Nelson, Douglas Kondziolka, Lawrence Wechsler, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 11, 2021
Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MSJens Kuhle, Nadia Daizadeh, Pascal Benkert, et al.
Critical Care Medicine|May 25, 2012
Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trialBruno François, Charles-Edouard Luyt, Anthony Dugard, et al.
Therapeutic Advances in Neurological Disorders|May 26, 2021
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trialAlasdair J Coles, Douglas L Arnold, Ann D Bass, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2019
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studiesGiancarlo Comi, Raed Alroughani, Aaron L Boster, et al.
Science Translational Medicine|December 21, 2022
Mitochondrial augmentation of hematopoietic stem cells in children with single large-scale mitochondrial DNA deletion syndromesElad Jacoby, Omer Bar-Yosef, Noah Gruber, et al.
Pageof 1